ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome

Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases

(2012) Véronique Gelsi-Boyer et al.   Journal of Hematology & Oncology

New mutations and pathogenesis of myeloproliferative neoplasms

(2011) W. Vainchenker et al.   BLOOD

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category

(2011) K. H. Metzeler et al.   BLOOD

Identification of a Novel TP53 Cancer Susceptibility Mutation Through Whole-Genome Sequencing of a Patient With Therapy-Related AML

(2011) Daniel C. Link   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Prognostic Significance of ASXL1 Mutations in Patients With Myelodysplastic Syndromes

(2011) Felicitas Thol et al.   JOURNAL OF CLINICAL ONCOLOGY

Strategy for Robust Detection of Insertions, Deletions, and Point Mutations in CEBPA, a GC-Rich Content Gene, Using 454 Next-Generation Deep-Sequencing Technology

(2011) Vera Grossmann et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemia

(2011) F Damm et al.   LEUKEMIA

A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases

(2011) V Grossmann et al.   LEUKEMIA

Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms

(2011) O Abdel-Wahab et al.   LEUKEMIA

The role of multiparameter flow cytometry for disease monitoring in AML

(2010) Wolfgang Kern et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status

(2010) S. Schnittger et al.   BLOOD

Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations

(2010) W.-C. Chou et al.   BLOOD

RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis

(2010) S. Schnittger et al.   BLOOD

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

(2010) D. Grimwade et al.   BLOOD

Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias

(2010) Julien Rocquain et al.   BMC CANCER

ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia

(2010) Véronique Gelsi-Boyer et al.   BRITISH JOURNAL OF HAEMATOLOGY

Genetic Analysis of Transforming Events That Convert Chronic Myeloproliferative Neoplasms to Leukemias

(2010) O. Abdel-Wahab et al.   CANCER RESEARCH

IDH1 and IDH2 mutations in myeloid neoplasms - Novel paradigms and clinical implications

(2010) M. Cazzola   HAEMATOLOGICA

Prognostic Impact of Isocitrate Dehydrogenase Enzyme Isoforms 1 and 2 Mutations in Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group

(2010) Nicolas Boissel et al.   JOURNAL OF CLINICAL ONCOLOGY

Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 72.8% of Chronic Myelomonocytic Leukemia by Detecting Frequent Alterations in TET2, CBL, RAS, and RUNX1

(2010) Alexander Kohlmann et al.   JOURNAL OF CLINICAL ONCOLOGY

The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration

(2010) O Abdel-Wahab et al.   LEUKEMIA

Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia

(2010) J Boultwood et al.   LEUKEMIA

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

(2010) Thomas Ernst et al.   NATURE GENETICS

A method and server for predicting damaging missense mutations

(2010) Ivan A Adzhubei et al.   NATURE METHODS

DNMT3AMutations in Acute Myeloid Leukemia

(2010) Timothy J. Ley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML

(2009) S. Schnittger et al.   BLOOD

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations

(2009) J.-L. Tang et al.   BLOOD

Mutations of polycomb-associated geneASXL1in myelodysplastic syndromes and chronic myelomonocytic leukaemia

(2009) Véronique Gelsi-Boyer et al.   BRITISH JOURNAL OF HAEMATOLOGY

ASXL1 Represses Retinoic Acid Receptor-mediated Transcription through Associating with HP1 and LSD1

(2009) Sang-Wang Lee et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias

(2009) N Carbuccia et al.   LEUKEMIA

Mutations of ASXL1 gene in myeloproliferative neoplasms

(2009) N Carbuccia et al.   LEUKEMIA

Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications

(2009) B Falini et al.   LEUKEMIA

A genome-wide perspective of genetic variation in human metabolism

(2009) Thomas Illig et al.   NATURE GENETICS

Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm

(2009) Prateek Kumar et al.   Nature Protocols

Mutation inTET2in Myeloid Cancers

(2009) François Delhommeau et al.   NEW ENGLAND JOURNAL OF MEDICINE